Source:http://linkedlifedata.com/resource/pubmed/id/14758097
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2004-2-3
|
pubmed:abstractText |
The risk stratification criteria of the American Association of Cardiovascular and Pulmonary Rehabilitation include guidelines to be used in stratifying cardiac rehabilitation (CR) patients for risk of disease progression (long term) and clinical events (short term). Noncardiac comorbidities are not included as indicators in these criteria. This study was designed to ascertain the prevalence of noncardiac comorbidities among CR patients, and to assess their relation to the current risk stratification algorithm for clinical events.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0883-9212
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
8-13; quiz 14-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14758097-Age Factors,
pubmed-meshheading:14758097-Aged,
pubmed-meshheading:14758097-Comorbidity,
pubmed-meshheading:14758097-Disease Progression,
pubmed-meshheading:14758097-Female,
pubmed-meshheading:14758097-Heart Diseases,
pubmed-meshheading:14758097-Humans,
pubmed-meshheading:14758097-Male,
pubmed-meshheading:14758097-Middle Aged,
pubmed-meshheading:14758097-Predictive Value of Tests,
pubmed-meshheading:14758097-Risk Factors,
pubmed-meshheading:14758097-Sex Factors,
pubmed-meshheading:14758097-Stroke Volume,
pubmed-meshheading:14758097-Treatment Outcome
|
pubmed:articleTitle |
Optimizing risk stratification in cardiac rehabilitation with inclusion of a comorbidity index.
|
pubmed:affiliation |
Division of Cardiovascular Disease, University of Alabama at Birmingham, 35294-0007, USA. gzoghbi@cardio.dom.uab.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase II
|